LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.48 -5.73

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.45

Max

1.49

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+220.95% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	48M 174M
Eelmine avamishind	7.21
Eelmine sulgemishind	1.48

Uudiste sentiment

By Acuity

81%

19%

323 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. märts 2026, 23:35 UTC

Uudisväärsed sündmused

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

1. märts 2026, 23:39 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1. märts 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

1. märts 2026, 23:24 UTC

Market Talk

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. märts 2026, 23:21 UTC

Market Talk

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1. märts 2026, 23:19 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1. märts 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1. märts 2026, 22:55 UTC

Uudisväärsed sündmused

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1. märts 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1. märts 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1. märts 2026, 22:38 UTC

Market Talk

Uudisväärsed sündmused

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1. märts 2026, 22:21 UTC

Tulu

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1. märts 2026, 22:17 UTC

Market Talk

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1. märts 2026, 22:00 UTC

Market Talk

Uudisväärsed sündmused

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1. märts 2026, 21:40 UTC

Market Talk

Uudisväärsed sündmused

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1. märts 2026, 21:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1. märts 2026, 21:30 UTC

Market Talk

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1. märts 2026, 21:27 UTC

Market Talk

Uudisväärsed sündmused

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1. märts 2026, 21:19 UTC

Market Talk

Uudisväärsed sündmused

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1. märts 2026, 20:58 UTC

Market Talk

Uudisväärsed sündmused

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1. märts 2026, 20:40 UTC

Market Talk

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1. märts 2026, 20:24 UTC

Market Talk

Uudisväärsed sündmused

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

220.95% tõus

12 kuu keskmine prognoos

Keskmine 4.75 USD 220.95%

Kõrge 7 USD

Madal 2.5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

323 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.